3. Epidemiology of IBs
• 10-20% of adults
• 2-3times higher in women
• Common age:30-50yr
• More common in whites then blacks
• Decreased incidence by increasing age
4. Pathophysiology of IBS
1. Visceral hypersensivity
2. Brain gut dysregulation
3. Immune&inflammatory
mediators
4. Post infection
8. Clinical manifestations of IBS
I. Abdominal Pain
II. Altered bowel habits
III. Gas and flatulence
IV.Upper GI symptoms
9. Abdominal pain in IBS
oExacerbated by eating or emotional
stress
oHighly variable in intensity and location
oMild enough to be ignored or it may
interfere with daily activities
10. Altered bowel habits & GAS and flatulence in
IBS
• Constipation alternating with diarrhea
• Episodic, but eventually it becomes continuous and
increasingly intractable to treatment with laxatives
• Abdominal distention and increased belching or flatulence
• Normal amount of intestinal gas
• Impaired transit and tolerance of intestinal gas loads
11. Upper GI symptoms in IBS
• 25 and 50% of patients dyspepsia, heartburn,
nausea, and vomiting
• Normal nocturnal motor pattern
• high incidence of abnormalities in the small
bowel during the diurnal (waking) period
18. Medical treatment of IBS
1. Antispasmodic drug
oHyoscyamine 0.25mg-0.125mg BID
oDicyclomine 10-20mg QID
oMethscopalamine 2.5-5mg daily before meal
2.Antidiarrhea agent
oLoperamide 2mg-4mg QID
oOpiates
19. Medical treatment of IBS
3.Anticonstipation agent
oLubiprostone 8mcg BID
oLinaclotid 290mcg OD
oAvoid Osmotic
laxatives such as Milk of
magnesia,Lactulose
20. Medical treatment of IBS
4.Psychotropic Agent
TCA:10-150mg OD
oImipiramine
oDesipramine
oNortryptyline
SSRI:
oParoxetine 10-20mg daily
oFluoxetine 20-40mg daily
oEscitalopram 5-20mg daily
21. Medical treatment of IBS
5-Selective serotonin receptor r antagonist
• Alosetron 1mg OD or BID
6-Selective serotonin receptor agonist
• Tegaserod 6mg BID
22. Medical treatment of IBS
7-Nonabsorbable Antibiotics
• Rifaximin 550mgTID
8-Probiotics
• Bifidobacterium infantis BID